NPPA's Order S.O. 5690(E) of 17 October 2026 caps the trade margin on 137 non-scheduled anti-cancer medicines, patented ones included, at 30% of MRP, with revised prices effective 9 November 2026.
By 4 November, 70 companies had reported revised MRPs for 1,136 SKUs of 120 drugs: average cuts of 20% to 70%, a highest cut of 96.45%, and estimated savings of Rs 3,357.49 crore.
The order rests on Paragraph 19 of the Drugs (Prices Control) Order 2013, the extraordinary public-interest power, and extends a 2019 pilot that covered 42 drugs.
New prices are worked out from each medicine's average distributor price of March 2026, with GST added on top of the capped margin.
The gap between what a manufacturer charges a stockist or distributor and the MRP a patient pays, excluding GST. Capping it trims supply-chain mark-ups, not the manufacturer's selling price.
| Aspect | Scheduled medicines | Non-scheduled medicines |
|---|---|---|
| Definition | In the First Schedule of DPCO 2013, which is the NLEM 2022 | Outside the First Schedule |
| Normal control | Government fixes a ceiling price | Price monitoring under Paragraph 20 |
| Limit | Ceiling price | MRP rise capped at 10% in twelve months; any excess must be brought back |
| Extra power | Paragraph 19 | Paragraph 19, used for the 2019 and 2026 margin caps |
Parent power under which the DPCO is issued
Notified 15 May 2013 as S.O. 1221(E), superseding DPCO 1995
In extraordinary circumstances and public interest, Government may fix or change a ceiling or retail price for any drug, without waiting for the yearly WPI-linked revision
Monitors non-scheduled MRPs against the 10% annual limit
Substituted NLEM 2022 into Schedule I of the DPCO
Set up 29 August 1997; fixes prices and enforces the DPCO; attached office of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers
Health Ministry expert panel constituted in 2018 to revise the NLEM
Autonomous body under the Health Ministry, founded in 1950 as Chittaranjan Cancer Hospital; second campus operates in Kolkata
ICMR programme started in December 1981; coordinated by ICMR-NCDIR, Bengaluru, since 2011
Proof of concept on 42 non-scheduled anti-cancer drugs
Key: NPPA reported cuts of up to 90% across 526 brands
Priority medicines list, first made in 1996; revised 2003, 2011, 2015, 2022
Key: NLEM 2022 was released on 13 September 2022 with 384 medicines; this backgrounder gives 388
NPPA's medicine-price app, introduced in 2017
Key: Version 2.0 launched on 29 August 2022 with a consumer complaint module
Low-cost generics; launched in 2008 under the Department of Pharmaceuticals
Key: 20,149 Kendras (30 June 2026); 2,110 medicines and 315 surgicals; 25,000-Kendra target by March 2027
Affordable Medicines and Reliable Implants for Treatment; launched 2015 by the Health Ministry, run by HLL Lifecare
Key: 285 outlets in 24 States and four UTs; 6,500+ products at discounts averaging up to 50%
Rs 5 lakh per family per year for the poorest 40% and everyone aged 70+
Key: 1,961 procedures across 27 specialties; 19.5 lakh medical-oncology admissions worth about Rs 2,926 crore (4 November 2026)
Primary health centres that screen people over 30 for oral, breast and cervical cancer, through ASHAs and ANMs
Key: 1.86 lakh+ functional (12 August 2026); screenings to July 2026: oral 36.11 crore, breast 16.94 crore, cervical 9.31 crore
Government teleconsultation platform, including oncology care
Key: Over 50 crore patients served (21 October 2026)
Specialist treatment capacity beyond the district level
Key: Tata Memorial Centre hospitals at Varanasi, Visakhapatnam, New Chandigarh, Guwahati, Sangrur and Muzaffarpur; National Cancer Institute, Jhajjar; cancer services at all 22 new AIIMS
Non-communicable disease screening and care
Key: 770 district NCD clinics, 6,410 CHC clinics, 524 Day Care Cancer Centres; 19 State Cancer Institutes and 20 Tertiary Care Cancer Centres approved
Launched 28 February 2026 from Ajmer for about 1.2 crore girls aged 14, across all 36 States/UTs
Key: Single-dose Gardasil; 80 lakh+ free doses by 11 September 2026
GS Paper 2 > Health > Access to Medicines; GS Paper 3 > Economy > Price Regulation
General Awareness > Government Bodies
Current Affairs > Regulators and Pricing
In India, markets in agricultural products are regulated under the
Answer: Agricultural Produce Market Committee Act enacted by States
A medicine outside DPCO's First Schedule, regulated by price monitoring rather than a ceiling price.
Capping supply-chain mark-up so MRP falls without directly fixing the manufacturer's price.
DPCO's extraordinary public-interest pricing power.
National List of Essential Medicines, which forms Schedule I of DPCO 2013.